Abstract
1045O - A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have